1. Home
  2. ASLE vs CABA Comparison

ASLE vs CABA Comparison

Compare ASLE & CABA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo AerSale Corporation

ASLE

AerSale Corporation

HOLD

Current Price

$6.31

Market Cap

296.8M

ML Signal

HOLD

Logo Cabaletta Bio Inc.

CABA

Cabaletta Bio Inc.

HOLD

Current Price

$3.13

Market Cap

319.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ASLE
CABA
Founded
2008
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Specialties
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
296.8M
319.6M
IPO Year
2018
2019

Fundamental Metrics

Financial Performance
Metric
ASLE
CABA
Price
$6.31
$3.13
Analyst Decision
Hold
Strong Buy
Analyst Count
2
6
Target Price
$7.00
$14.50
AVG Volume (30 Days)
271.7K
1.9M
Earning Date
05-06-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
63.64
10.26
EPS
0.18
N/A
Revenue
$335,286,000.00
N/A
Revenue This Year
$23.41
N/A
Revenue Next Year
$6.80
N/A
P/E Ratio
$35.00
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.56
$1.01
52 Week High
$9.08
$3.78

Technical Indicators

Market Signals
Indicator
ASLE
CABA
Relative Strength Index (RSI) 42.22 56.36
Support Level $5.67 $2.11
Resistance Level $6.56 $3.34
Average True Range (ATR) 0.16 0.24
MACD 0.04 0.02
Stochastic Oscillator 79.79 85.53

Price Performance

Historical Comparison
ASLE
CABA

About ASLE AerSale Corporation

AerSale Corp offers full-service support to owners and operators of mid-life commercial aircraft. It specializes in the sale, lease, and exchange of used aircraft, engines, and components, in addition to providing various maintenance, repair, and overhaul, and engineering services for commercial aircraft and components. AerSale also offers asset management services to owners of end-of-life aircraft and engine portfolios. The company has two reportable segments: Asset Management Solutions and TechOps. Maximum revenue is generated from the Asset Management Solutions segment, which comprises activities to extract value from strategic asset acquisitions through leasing, trading, or disassembling for product sales. Geographically, the company derives maximum revenue from its domestic market.

About CABA Cabaletta Bio Inc.

Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells, that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) that have the potential to be applied across a broad range of autoimmune diseases.

Share on Social Networks: